{"id":"NCT00075218","sponsor":"Pfizer","briefTitle":"A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-12","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2004-01-08","resultsPosted":"2009-09-28","lastUpdate":"2009-09-28"},"enrollment":361,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastrointestinal Stromal Tumor"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"SU011248","otherNames":[]}],"arms":[{"label":"B","type":"PLACEBO_COMPARATOR"},{"label":"A","type":"ACTIVE_COMPARATOR"}],"summary":"A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment.","primaryOutcome":{"measure":"Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase","timeFrame":"Day 28 of each 6-week cycle : duration of double-blind treatment phase","effectByArm":[{"arm":"Sunitinib Double-Blind Treatment","deltaMin":27.3,"sd":null},{"arm":"Placebo Double-Blind Treatment","deltaMin":6.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":61,"countries":["United States","Australia","Belgium","Canada","France","Italy","Netherlands","Singapore","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["17046465"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181004&StudyName=A%20Study%20To%20Assess%20The%20Safety%20And%20Efficacy%20Of%20SU11248%20In%20Patients%20With%20Gastrointestinal%20Stromal%20Tumors%20%28GIST%29"]},"adverseEventsSummary":{"seriousAny":{"events":83},"commonTop":["Fatigue","Diarrhoea","Abdominal pain","Nausea","Anorexia"]}}